Lone Star Bio

Found 17,037 articles

• 

  BioSpace Launches 2022 Hotbed Maps to Highlight Thriving Life Sciences Clusters

  1/18/2022

  As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.

• Virogentics Inc. Announces Pilot Clinical Trial of ITV-1 at National Center for Endocrinology in Bulgaria and Expansion of Nutraceutical Line

  5/8/2023

  Enzolytics, Inc. announced that the Company's wholly owned subsidiary, Virogenetics (VIRO), will be conducting a pilot clinical trial test for the state owned Bulgarian National Center for Endocrinology to gauge the effectiveness of the ITV-1 immunotherapy on Diabetes.

• Encouraging Data from Lumos Pharma OraGrowtH Trials Presented at Annual Pediatric Endocrine Society Meeting (PES)

  5/8/2023

  Lumos Pharma, Inc. announced that interim data from its OraGrowtH210 Trial were reviewed in an oral presentation at the 2023 Annual Meeting of the Pediatric Endocrine Society, held in San Diego, California, May 5-8, 2023.

• Aravive to Host Virtual KOL Event on its Late-Stage Oncology Asset Batiraxcept

  5/8/2023

  Aravive, Inc., a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, announced it will host a virtual Key Opinion Leader event on its late-stage oncology asset, batiraxcept, on Wednesday, May 24, 2023 at 1:00pm ET.

• Natera Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility of Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting

  5/8/2023

  Natera, Inc. today announced the publication of a new paper 1 in Cancer Cell from the I-SPY2 trial, highlighting the prognostic and predictive utility of Natera’s personalized and tumor-informed, molecular residual disease (MRD) test, Signatera, in locally advanced breast cancer patients receiving neoadjuvant chemotherapy (NAC, treatment before surgery).

• Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer

  5/8/2023

  Marker Therapeutics, Inc. today announced the appointment of Monic Stuart, M.D., as its new Chief Medical Officer.

• New Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin A

  5/8/2023

  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced new data from European researchers that highlight the bioactivity of simufilam on the filamin A (FLNA) protein.

• Hummingbird Bioscience to Present Preclinical Proof of Concept for Potentially First-In-Class Antibody Targeting Autoimmune Diseases

  5/8/2023

  Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, announced an upcoming poster presentation at IMMUNOLOGY2023™.

• HeartSciences to Participate at the Inaugural EF Hutton Global Conference

  5/8/2023

  Heart Test Laboratories, Inc. today announces that CEO, Andrew Simpson, will participate at the Inaugural EF Hutton Global Conference being held May 10 – 11, 2023, at the Plaza Hotel in New York City.

• Genprex to Participate and Present at Upcoming May Industry and Investor Conferences

  5/8/2023

  Genprex, Inc. today announced the Company's participation in the following upcoming industry and investor conferences to be held in May 2023.

• Renibus Reports Positive Final Results from Phase 2 Study of RBT-1, a First-in-Class Preconditioning Agent for Patients Undergoing Cardiothoracic Surgery, at the American Association for Thoracic Surgery (AATS) Meeting

  5/7/2023

  Renibus Therapeutics® presented positive final results from a Phase 2 trial evaluating RBT-1 in patients undergoing elective cardiac surgery during an oral presentation at the 103rd Annual American Association for Thoracic Surgery meeting at the Los Angeles Convention Center, taking place May 6-9, 2023 in Los Angeles, CA.

• Savara Announces New Employment Inducement Grant - May 5, 2023

  5/5/2023

  Savara Inc. today announced the grant of inducement awards to two new employees.

• Research to Be Presented at ISPOR 2023 Illuminates the Economic Costs of Melanoma and Non-Small Cell Lung Cancer and Provides Insights That Can Help Strengthen the Quality and Approach to Real-World Evidence Generation

  5/5/2023

  Ontada®, a McKesson business dedicated to leveraging oncology real-world data, real-world evidence, clinical education, and provider technology to transform the fight against cancer, will be presenting research at ISPOR 2023, The Professional Society for Health Economics and Outcomes Research Annual Meeting taking place in Boston on May 7-10.

• Bio-Path Holdings to Announce First Quarter 2023 Financial Results on May 12, 2023

  5/5/2023

  Bio-Path Holdings, Inc. today announced that it will host a live conference call and audio webcast on Friday, May 12, 2023 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2023 and to provide a business overview.

• TFF Pharmaceuticals Enters into CRADA with the National Institute of Environmental Health Sciences to Develop Dry Powder Formulations of Hyaluronan to Prevent and Treat Respiratory Diseases

  5/4/2023

  TFF Pharmaceuticals, Inc. today announced that it has entered into a Collaborative Research and Development Agreement (CRADA) with the National Institute of Environmental Health Sciences (NIEHS) to develop respirable, dry powder formulations of high molecular weight hyaluronan (HMW-HA) for treating or preventing respiratory diseases.

• Moleculin to Report First Quarter Financial Results on May 11, 2023 and Host Conference Call and Webcast

  5/4/2023

  Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it will report its financial results for the first quarter ended March 31, 2023, on Thursday, May 11, 2023.

• Taysha Gene Therapies to Release First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 11

  5/4/2023

  Taysha Gene Therapies, Inc. (Nasdaq: TSHA) today announced that it will report its financial results for the first quarter ended March 31, 2023, and host a corporate update conference call and webcast on Thursday, May 11, 2023, at 4:30 PM Eastern Time.

• Sanara MedTech Inc. Announces First Quarter Earnings Release and Conference Call Dates

  5/3/2023

  Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI) announced today details for the release of its results for the quarter ended March 31, 2023.

• NuProbe BDA Technology Enables Highly Sensitive Detection of Low-Level Variants for Oncology Research

  5/3/2023

  NuProbe, a genomics company developing ultrasensitive research assays for detecting and monitoring low-frequency mutations, gene fusions, and copy number alterations (CNAs), recently published research demonstrating capabilities of their blocker displacement amplification (BDA) technology for detection of a JAK2 mutation using qPCR.

• Study Demonstrates Use of DecisionDx®-Melanoma to Guide Treatment Decisions Resulted in Earlier Detection of Melanoma with Decreased Metastatic Tumor Burden Compared to Patients Without Surveillance Imaging Studies

  5/3/2023

  Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of an independent, multi-center study in the Archives of Dermatological Research providing a direct chain of evidence that use of DecisionDx®-Melanoma test results to guide radiological surveillance could lead to improved patient outcomes.